Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 3/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291328 | 0.85 | CA1 (0.38) | MEN1KMT2ATSHRALDH1A1KDM4E | |
| SCHEMBL4294740 | 0.84 | MAN1B1 (0.43) | POLBGAA | |
| SCHEMBL4289461 | 0.83 | EBP (0.40) | KMT2ATSHRGAAMAPT | |
| SCHEMBL4750102 | 0.83 | MAPT (0.41) | MEN1KMT2AGAAMAPT | |
| SCHEMBL4291053 | 0.80 | KDM4E (0.39) | MEN1KMT2APOLBTSHRGAA | |
| SCHEMBL4289730 | 0.80 | MAPT (0.43) | MEN1KMT2AGAAALDH1A1MAPT | |
| SCHEMBL4289734 | 0.80 | MAPT (0.43) | MEN1KMT2AGAAALDH1A1MAPT | |
| SCHEMBL4283875 | 0.79 | MEN1 (0.42) | MEN1KMT2APOLBTSHRGRIN2B | |
| SCHEMBL4281693 | 0.77 | CCR3 (0.39) | MEN1KMT2AGRIN2BGAAALDH1A1 | |
| SCHEMBL4284144 | 0.76 | EPHX2 (0.43) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MEN1 1254/4885KMT2A 1049/4885POLB 3799/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MEN1 1254/4885KMT2A 1049/4885POLB 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.